[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Xie Jian, President and COO of Fulgent Genetics (FLGT) reported a sale of 696 shares on 08/25/2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016. After the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust, of which he serves on the investment committee and for which he disclaims beneficial interest except for any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

Positive

• Sale documented as tax-withholding on RSU vesting, indicating administrative rather than opportunistic trading
• Substantial remaining ownership: 366,448 shares directly and 220,816 indirectly via trust
• Complete disclosure of sale price range ($21.46–$21.57) and weighted-average price ($21.5016)

Negative

• Reduction of direct holdings by 696 shares recorded on 08/25/2025

Insights

Financial Analyst

TL;DR: Routine insider sale of 696 shares to cover RSU tax withholding; ownership remains substantial.

The reported disposition is explicitly a sale to satisfy tax withholding on RSU vesting, not an open-market reduction of long-term holdings. The weighted-average sale price of $21.5016 and the small share count (696) indicate the transaction is administrative in nature. Post-transaction direct ownership of 366,448 shares plus 220,816 indirectly held suggests continued material insider alignment with shareholders. No derivative transactions or other dispositions are reported.

Corporate Governance Expert

TL;DR: Disclosure is standard and complete: sale is identified, source of sale explained, and trust holdings disclosed.

The filing clearly states the purpose of the sale (tax withholding) and discloses indirect holdings via The Hsieh Family Dynasty Trust, including the reporting person’s role on the trust investment committee and disclaimer of beneficial interest beyond pecuniary exposure. Signature by an attorney-in-fact is documented. This meets Section 16 transparency requirements and does not indicate any governance or compliance irregularity based on the provided facts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		S		696(1)	D	$21.5016(2)	366,448	D
Common Stock								220,816	I	By Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

2. The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for FLGT on 08/26/2025?

The filing reports transactions by Xie Jian, President and COO, and the form was signed by an attorney-in-fact on 08/26/2025.

Why were 696 shares of FLGT sold on 08/25/2025?

The 696 shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/23/2023.

At what price were the FLGT shares sold?

Shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, with a reported weighted-average price of $21.5016.

How many FLGT shares does Xie Jian own after the transaction?

Following the sale, the reporting person beneficially owns 366,448 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust.

What is the nature of the indirect holdings disclosed?

The indirect holdings are held by The Hsieh Family Dynasty Trust dated January 27, 2010; Mr. Xie serves on the trust’s investment committee and disclaims beneficial interest except for any pecuniary interest.